Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2024
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement).
Key Financial Metrics and Debt Structure
This filing details a new senior secured term loan facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Total Facility Size: Up to $200.0 million in senior secured term loans.
- Initial Funding: $30.0 million advanced on the Closing Date (November 6, 2024).
- Interest Rate: Floating annual rate equal to the greater of 8.25% or Prime Rate + 1.75%.
- Payment-in-Kind (PIK) Option: Borrower may reduce cash interest by up to 2.00% per annum, with the reduction added to principal as PIK interest at 1.10x the reduction amount.
- Maturity Date: December 1, 2029.
- Repayment Terms: Monthly interest-only payments through December 1, 2028 (extendable to December 1, 2029 if Tranche 3 Milestone is achieved).
- Collateral: First-priority security interest in all tangible and intangible assets, excluding intellectual property.
Material Changes and Loan Tranches
The agreement establishes a multi-tranche structure contingent on future milestones and lender discretion:
- Tranche 1: $30.0 million (Funded).
- Tranche 2: Up to $30.0 million available by September 15, 2026.
- Tranche 3: Up to $50.0 million available by December 15, 2026.
- Tranche 4: Up to $25.0 million available by June 15, 2027, subject to achieving the "Tranche 2 Milestone."
- Tranche 5: Up to $40.0 million available by December 15, 2027, subject to achieving the "Tranche 3 Milestone."
- Tranche 6: Up to $25.0 million available subject to Lenders' investment committee approval.
Covenants, Risks, and Management Commentary
Minimum Cash Covenant: The agreement requires the Borrower to maintain specific cash levels in controlled accounts starting January 1, 2027 (or January 1, 2028 if a certain milestone is met), provided the aggregate principal outstanding exceeds $50.0 million. This covenant is waived if the Company's market capitalization is greater than or equal to $1.0 billion.
Risks and Contingencies: Future funding is contingent upon achieving undefined milestones ("Tranche 2 Milestone" and "Tranche 3 Milestone") and lender discretion. The use of PIK interest increases the principal balance over time if elected. The loan is secured by substantially all assets except intellectual property.
Management Commentary: The filing incorporates a press release issued on November 8, 2024, regarding the agreement. No specific operational outlook or revenue guidance is provided in this text.
Investor Verification Checklist
- Verify the specific definitions of the "Tranche 2 Milestone" and "Tranche 3 Milestone" in the full Loan Agreement (Exhibit 10.1) to assess the likelihood of future funding.
- Review the Company's current market capitalization to determine if the minimum cash covenant is currently waived.
- Assess the impact of potential PIK interest on future debt service obligations and principal balance.
- Confirm the status of the Company's intellectual property, as it is explicitly excluded from the collateral package.
- Monitor the Company's cash burn rate relative to the $30.0 million initial advance to gauge runway before the next tranche availability dates.